Experimental immune therapy offers hope for transplant patients with uncontrolled rejection
NCT ID NCT01937468
Summary
This early-stage safety study is testing a new combination treatment for chronic graft-versus-host disease (cGVHD) that doesn't improve with standard steroid therapy. The treatment involves giving patients special anti-inflammatory immune cells (Tregs) collected from their original stem cell donor, followed by 8 weeks of daily low-dose IL-2 injections under the skin. Researchers aim to find the safest and most effective dose of this cell-plus-drug combination to help control the donor immune system's attack on the patient's body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Insitute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.